Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry D Anderson

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
Blood|August 1, 2025
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapyBinod Dhakal, Othman Salim Akhtar, David Fandrei, et al.
Blood Cancer Journal|June 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy ConsortiumDanai Dima, Mariola A Vazquez-Martinez, James A Davis, et al.
Blood Advances|April 8, 2025
Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal ImpairmentDanai Dima, Aimaz Afrough, Utkarsh Goel, et al.
Blood Advances|February 24, 2023
Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysisBrittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple MyelomaDoris K Hansen, Lauren C Peres, Danai Dima, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2025
Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple MyelomaDoris K Hansen, Lauren C Peres, Danai Dima, et al.
Blood Cancer Journal|May 9, 2025
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy ConsortiumOren Pasvolsky, Danai Dima, Lei Feng, et al.
Blood Cancer Journal|November 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experienceAimaz Afrough, Danai Dima, Beatrice Razzo, et al.
Blood Advances|March 15, 2025
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myelomaRahul Banerjee, Alicia Richards, Shonali Midha, et al.
Blood Cancer Discovery|July 9, 2025
Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy ConsortiumBeatrice M Razzo, Shonali Midha, Andrew J Portuguese, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Blood|August 1, 2025
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapyBinod Dhakal, Othman Salim Akhtar, David Fandrei, et al.
Blood Cancer Journal|June 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy ConsortiumDanai Dima, Mariola A Vazquez-Martinez, James A Davis, et al.
Blood Advances|April 8, 2025
Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal ImpairmentDanai Dima, Aimaz Afrough, Utkarsh Goel, et al.
Blood Advances|February 24, 2023
Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysisBrittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple MyelomaDoris K Hansen, Lauren C Peres, Danai Dima, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2025
Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple MyelomaDoris K Hansen, Lauren C Peres, Danai Dima, et al.
Blood Cancer Journal|May 9, 2025
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy ConsortiumOren Pasvolsky, Danai Dima, Lei Feng, et al.
Blood Cancer Journal|November 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experienceAimaz Afrough, Danai Dima, Beatrice Razzo, et al.
Blood Advances|March 15, 2025
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myelomaRahul Banerjee, Alicia Richards, Shonali Midha, et al.
Blood Cancer Discovery|July 9, 2025
Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy ConsortiumBeatrice M Razzo, Shonali Midha, Andrew J Portuguese, et al.
Pageof 12